Literature DB >> 9459162

Analysis of histological therapeutic effect, apoptosis rate and p53 status after combined treatment with radiation, hyperthermia and 5-fluorouracil suppositories for advanced rectal cancers.

C Sakakura1, K Koide, D Ichikawa, T Wakasa, M Shirasu, A Kimura, H Taniguchi, A Hagiwara, T Yamaguchi, J Inazawa, T Abe, T Takahashi, E Otsuji.   

Abstract

The tumour-suppressor gene p53 encodes a transcription factor that plays a critical role in the induction of G1 cell cycle arrest and apoptosis after DNA damage. To clarify the role of the p53 gene and apoptosis in combined hyperthermia, chemotherapy and radiation (hyperthermochemoradiotherapy, HCR therapy) for rectal cancer, we examined the histological response, rate of apoptosis, DNA fragmentation and p53 status in tumours from 28 patients undergoing HCR therapy before surgery and from 22 patients who did not have preoperative treatment. The therapeutic effect of HCR therapy was closely correlated with the rate of apoptosis; the correlation was statistically significant, suggesting that this effect occurs through apoptosis. The incidence of p53 mutations in the treated group were as follows: in tumours resistant to HCR therapy, four of seven (57.1%); intermediately sensitive, 7 of 13 (53.9%); or sensitive, three of eight (37.5%), suggesting that the therapeutic effect and apoptosis rate were related to the p53 status of the tumours to some extent, but the relation was not statistically significant. In the 22 control tumours (non-treated group), the apoptosis rate was 2.0 +/- 1.1%, and there was no significant difference in p53 status compared with the HCR group. Our study indicates that the pathological response to HCR therapy correlates with the rate of apoptosis with statistical significance and that it induces the therapeutic effect more significantly in rectal cancer cells with wild-type p53, although HCR therapy-induced apoptosis also occurs in some rectal cancers with mutated p53. Therefore, this combination therapy can induce an additive or synergistic anti-tumour effect in rectal cancers with wild-type p53 as well as in those with mutated p53 through apoptosis, offering new therapeutic opportunities and a better prognosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9459162      PMCID: PMC2151276          DOI: 10.1038/bjc.1998.25

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  37 in total

1.  Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia.

Authors:  M A Barry; C A Behnke; A Eastman
Journal:  Biochem Pharmacol       Date:  1990-11-15       Impact factor: 5.858

2.  Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial.

Authors:  L Påhlman; B Glimelius
Journal:  Ann Surg       Date:  1990-02       Impact factor: 12.969

3.  Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC).

Authors:  A Gérard; M Buyse; B Nordlinger; J Loygue; F Pène; P Kempf; J F Bosset; M Gignoux; J P Arnaud; C Desaive
Journal:  Ann Surg       Date:  1988-11       Impact factor: 12.969

4.  [Two allelic genes of human p53 code for proteins differing with respect to amino acid sequence].

Authors:  V L Bukhman; N N Ninkina; P M Chumakov
Journal:  Genetika       Date:  1988-12

5.  Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage.

Authors:  W J Slichenmyer; W G Nelson; R J Slebos; M B Kastan
Journal:  Cancer Res       Date:  1993-09-15       Impact factor: 12.701

6.  The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice.

Authors:  A J Merritt; C S Potten; C J Kemp; J A Hickman; A Balmain; D P Lane; P A Hall
Journal:  Cancer Res       Date:  1994-02-01       Impact factor: 12.701

7.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.

Authors:  S W Lowe; H E Ruley; T Jacks; D E Housman
Journal:  Cell       Date:  1993-09-24       Impact factor: 41.582

8.  A comparison of nonoperative vs. preoperative radiotherapy in rectal carcinoma. A 10-year randomized trial.

Authors:  J A Reis Neto; F A Quilici; J A Reis
Journal:  Dis Colon Rectum       Date:  1989-08       Impact factor: 4.585

9.  Preoperative use of 5-fluorouracil suppository for carcinoma of the rectum.

Authors:  T Takahashi; K Kohno; T Yamaguchi; T Narisawa
Journal:  Am J Surg       Date:  1982-02       Impact factor: 2.565

10.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.

Authors:  S J Baker; E R Fearon; J M Nigro; S R Hamilton; A C Preisinger; J M Jessup; P vanTuinen; D H Ledbetter; D F Barker; Y Nakamura; R White; B Vogelstein
Journal:  Science       Date:  1989-04-14       Impact factor: 47.728

View more
  6 in total

Review 1.  Germline and somatic genetic predictors of pathological response in neoadjuvant settings of rectal and esophageal cancers: systematic review and meta-analysis.

Authors:  L E Salnikova; D S Kolobkov
Journal:  Pharmacogenomics J       Date:  2015-06-30       Impact factor: 3.550

2.  Comparison of genomics and functional imaging from canine sarcomas treated with thermoradiotherapy predicts therapeutic response and identifies combination therapeutics.

Authors:  Jen-Tsan Chi; Donald E Thrall; Chen Jiang; Stacey Snyder; Diane Fels; Chelsea Landon; Linda McCall; Lan Lan; Marlene Hauck; James R MacFall; Benjamin L Viglianti; Mark W Dewhirst
Journal:  Clin Cancer Res       Date:  2011-02-03       Impact factor: 12.531

3.  Chromosomal copy number changes of locally advanced rectal cancers treated with preoperative chemoradiotherapy.

Authors:  Marian Grade; Jochen Gaedcke; Danny Wangsa; Sudhir Varma; Jaje Beckmann; Torsten Liersch; Clemens Hess; Heinz Becker; Michael J Difilippantonio; Thomas Ried; B Michael Ghadimi
Journal:  Cancer Genet Cytogenet       Date:  2009-08

Review 4.  P53 abnormalities and outcomes in colorectal cancer: a systematic review.

Authors:  F M Smith; R B Stephens; M J Kennedy; J V Reynolds
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

5.  p53 dynamics in single cells are temperature-sensitive.

Authors:  Marcel Jentsch; Petra Snyder; Caibin Sheng; Elena Cristiano; Alexander Loewer
Journal:  Sci Rep       Date:  2020-01-30       Impact factor: 4.379

6.  P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer.

Authors:  Min-Bin Chen; Xiao-Yang Wu; Rong Yu; Chen Li; Li-Qiang Wang; Wei Shen; Pei-Hua Lu
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.